Nihon Kohden (OTCMKTS:NHNKY – Get Free Report) was downgraded by equities research analysts at UBS Group from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.
Separately, Zacks Research upgraded shares of Nihon Kohden to a “hold” rating in a research note on Monday, April 27th. Two analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Nihon Kohden presently has an average rating of “Hold”.
Check Out Our Latest Stock Report on NHNKY
Nihon Kohden Stock Down 2.8%
Nihon Kohden (OTCMKTS:NHNKY – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.09). Nihon Kohden had a net margin of 5.90% and a return on equity of 9.08%. The firm had revenue of $297.47 million during the quarter, compared to analysts’ expectations of $299.98 million. As a group, equities analysts anticipate that Nihon Kohden will post 0.6 EPS for the current fiscal year.
About Nihon Kohden
Nihon Kohden Corporation is a Tokyo-based manufacturer of medical electronic equipment, founded in 1951. The company has built a reputation for innovation in patient monitoring and diagnostic systems, developing one of Japan’s earliest electrocardiogram (ECG) machines and pioneering transistor-based oscilloscopes for clinical use. Over the decades, Nihon Kohden has expanded its product portfolio to address a wide range of healthcare needs, from emergency response to intensive care and neurology.
The company’s core offerings include patient monitors, ECG and electroencephalograph (EEG) devices, defibrillators, infusion pumps, and neuromonitoring systems.
Featured Articles
- Five stocks we like better than Nihon Kohden
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Nihon Kohden Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nihon Kohden and related companies with MarketBeat.com's FREE daily email newsletter.
